PharmaNutra SpA (MIL:PHN) ROCE %: 22.62% (As of Mar. 2026)

What is PharmaNutra SpA ROCE %?

PharmaNutra SpA MIL:PHN -1.91% 85 ROCE % is 22.62% as of Mar. 2026. GuruFocus rates MIL:PHN with a GF Score™ of 85/100 and a GF Value™ of €71.38 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PharmaNutra SpA's annualized ROCE % for the quarter that ended in Mar. 2026 was 22.62%.

PharmaNutra SpA (MIL:PHN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PharmaNutra SpA ROCE % Related Terms

PharmaNutra SpA ROCE % Historical Data

* Premium members only.

The historical data trend for PharmaNutra SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaNutra SpA ROCE % Chart

PharmaNutra SpA Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

39.57

36.41

30.24

32.28

33.49

PharmaNutra SpA Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															18.67	47.75	35.76	36.35	22.62

85GF Score

PharmaNutra SpA MIL:PHN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmaNutra SpA ROCE % Calculation

PharmaNutra SpA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	30.852	/	( ( (117.408 - 27.34)	+	(125.233 - 31.033) )	/ 2 )
	=	30.852	/	( (90.068	+	94.2)	/ 2 )
	=	30.852	/	92.134
	=	33.49 %

PharmaNutra SpA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	21.596	/	( ( (125.233 - 31.033)	+	(128.125 - 31.395) )	/ 2 )
	=	21.596	/	( ( 94.2	+	96.73 )	/ 2 )
	=	21.596	/	95.465
	=	22.62 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 22.62% mean?

PharmaNutra SpA (MIL:PHN) has a ROCE % of 22.62% as of Mar. 2026.

Is PharmaNutra SpA's ROCE % too high?

PharmaNutra SpA's current ROCE % is 22.62%. The Drug Manufacturers industry median ROCE % is 7.00. PharmaNutra SpA's value of 22.62% is 223.4% above this industry median. Overall, PharmaNutra SpA has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does PharmaNutra SpA's ROCE % compare to ZTS and UTHR?

PharmaNutra SpA's ROCE % of 22.62% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. PharmaNutra SpA's value of 22.62% is 223.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current ROCE % of 22.62% is 223.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current ROCE % is 22.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmaNutra SpA stock overvalued right now?

Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €71.38, compared to a current price of €87.20 — trading 22.2% above its estimated fair value. The current ROCE % is 22.62% and 223.4% above the Drug Manufacturers industry median of 7.00. PharmaNutra SpA's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current ROCE % is 22.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued. The current stock price of €87.20 is trading 22.2% above its estimated GF Value™ of €71.38. GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.

Key valuation signals for MIL:PHN:

ROCE %: 22.62%
GF Value™: €71.38 vs. price of €87.20 (22.2% above fair value)
GF Score™: 85/100 with 6 warning signs
Industry Position: 223.4% above the Drug Manufacturers median

No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaNutra SpA Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692 UTHR VTRS NSE:DIVISLAB OSTO:SOBI TSE:4507 NBIX NSE:TORNTPHARM XPAR:IPN SHSE:688506 SZSE:002001

Other Exchanges PHNm:UK 761:Germany

Address Via Campodavela 1, Pisa, ITA, 56122

Website https://www.pharmanutra.it

PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.

85GF Score

Get the complete analysis for MIL:PHN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€87.20

Price

€71.38

GF Value

View MIL:PHN Analysis

See ROCE % data for all stocks →